KZIA

1.90

37.68% 0.52

Handel nachbörslich: 1.88 -0.02 -1.05%

Kazia Therapeutics Limited Adr (KZIA)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$1.38

Offen:

$2.16

24-Stunden-Volumen:

103.76M

Relative Volume:

62.03

Marktkapitalisierung:

$10.34M

Einnahmen:

Nettoeinkommen (Verlust:

$-13.52M

KGV:

-2.5676

EPS:

-0.74

Netto-Cashflow:

$-10.03M

1W Leistung:

+29.25%

1M Leistung:

-38.71%

6M Leistung:

-49.56%

1J Leistung:

-36.11%

1-Tages-Spanne:

$1.73

$2.64

1-Wochen-Bereich:

$1.34

$2.64

52-Wochen-Spanne:

$1.32

$15.80

Kazia Therapeutics Limited Adr Stock (KZIA) Company Profile

Firmenname

Kazia Therapeutics Limited Adr

Sektor

Healthcare (1178)

Branche

Biotechnology (678)

Telefon

01161298780088

Adresse

140 WICKS RD, NEW SOUTH WALES 2113, NSW

Mitarbeiter

Twitter

@KaziaTx

Nächster Verdiensttermin

2024-11-04

Neueste SEC-Einreichungen

KZIA's Discussions on Twitter

Vergleichen Sie KZIA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
KZIA Kazia Therapeutics Limited Adr	1.90	10.34M	0	-13.52M	-10.03M	-0.74
VRTX Vertex Pharmaceuticals Inc	438.40	113.67B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	683.08	74.97B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	665.68	40.50B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	277.16	35.95B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	120.88	29.63B	3.30B	-501.07M	1.03B	-2.1146

Kazia Therapeutics Limited Adr Stock (KZIA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2021-10-14	Eingeleitet	Maxim Group	Buy
2021-01-05	Eingeleitet	H.C. Wainwright	Buy

Kazia Therapeutics Limited Adr Aktie (KZIA) Neueste Nachrichten

07:30 AM

2025-01-30 | Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer | NDAQ:KZIA | Press Release - Stockhouse Publishing

07:30 AM

Jan 14, 2025

Kazia Therapeutics Secures $2M Funding Through Direct Offering to Alumni Capital - StockTitan

Jan 14, 2025

Jan 10, 2025

Kazia Therapeutics secures $2 million in direct offering - Investing.com India

Jan 10, 2025

Kazia Therapeutics Secures $2M Funding Through Direct Offering at $1.50 Per ADS - StockTitan

Jan 10, 2025

Dec 31, 2024

Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday? - Yahoo Finance

Dec 31, 2024

Kazia aligns with FDA on glioblastoma drug study design - Investing.com India

Dec 31, 2024

SEC Form 424B3 filed by Kazia Therapeutics Limited - Quantisnow

Dec 31, 2024

Kazia's Brain Cancer Drug Paxalisib Shows 3.8-Month Survival Benefit, FDA Guides Phase 3 Path Forward - StockTitan

Dec 31, 2024

Dec 11, 2024

Kazia's Paxalisib Shows Promise in Breast Cancer Trial: Key Data Released at SABCS - StockTitan

Dec 11, 2024

Nov 04, 2024

Kazia sets FDA meeting for glioblastoma drug pathway - Investing.com India

Nov 04, 2024

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme - StockTitan

Nov 04, 2024

Oct 30, 2024

U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN

Oct 30, 2024

Oct 29, 2024

Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail

Oct 29, 2024

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN

Oct 29, 2024

Oct 28, 2024

Upcoming Stock Splits This Week (October 28 to November 1) – Stay Invested - Nasdaq

Oct 28, 2024

Oct 16, 2024

Ratios in Focus: Analyzing Kazia Therapeutics Limited ADR (KZIA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 16, 2024

Kazia Therapeutics Adjusts ADS Ratio to Boost Nasdaq Listing - Yahoo Finance

Oct 16, 2024

Kazia Therapeutics Stock Scheduled to Reverse Split on Monday, October 28th (NASDAQ:KZIA) - Defense World

Oct 16, 2024

Oct 11, 2024

B2i Digital Acting as Marketing Partner for Maxim Group's 2024 Healthcare Virtual Summit - Benzinga

Oct 11, 2024

Oct 02, 2024

Paxalisib shows promise in brain metastasis treatment - Investing.com

Oct 02, 2024

It makes sense and dollars to buy Kazia Therapeutics Limited ADR (KZIA) stock - SETE News

Oct 02, 2024

Market Recap: Kazia Therapeutics Limited ADR (KZIA)’s Positive Momentum, Closing at 0.43 - The Dwinnex

Oct 02, 2024

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American - StockTitan

Oct 02, 2024

Oct 01, 2024